Targeting PRC2 Enhances the Cytotoxic Capacity of Anti-CD19 CAR T Cells against Hematologic Malignancies

Autor(es):Mostrar menos -

Rodrigues Carvalho, Maria Leticia ; de Oliveira Andrade, Clara ; Cabral-Piccin, Mariela Pires ; Kinker, Gabriela Sarti ; Vitiello, Glauco Akelinghton Freire ; Goncalves Cambui, Raylane Adrielle ; de Macedo Abdo, Luiza ; Mannarino Correia, Eduardo ; da Silva Elias, Bruno Dalbelo ; Araujo, Emmanuel Vinicius Oliveira ; Chaves, Alexandre Silva ; Pereira, Pedro Henrique Barbosa ; Hajdu, Karina Lobo ; Rondinelli, Amanda ; Fagotti Gusmao, Arianne ; Marques Pierre, Maria Luisa ; Brasil-Costa, Igor ; Pouza Zanella, Caroline ; Moreira Lemos, Marta Maria ; Batista, Marjorie Vieira ; Filho, Jayr Schmidt ; Arrowsmith, Cheryl ; Cordeiro de Lima, Vladmir Claudio ; Bonamino, Martin Hernan ; da Silva Medina, Tiago

• Tipo de documento: Artigo Científico
• Fonte: Cancer Research; v. 85, n. 12, p. 16-pg., 2025-06-16.

Resumo

Chimeric antigen receptor (CAR) T-cell therapy is increasingly being adopted as a clinical modality for patients with relapsed/refractory hematologic malignancies. Despite the clinical efficacy of CAR T-cell therapy, a considerable fraction of patients still relapse during the first months following CAR T-cell infusion. The limited CAR T-cell efficiency is thought to relate to epigenetic mechanisms involved in T-cell suppression and dysfunction. In this study, screening of multiple epigenetic inhibitors revealed that targeting polycomb repressive complex 2 (PRC2) consistently induced the development of granzyme B+ effector memory CD8 T cells. Notably, PRC2 inhibition also promoted the long-term persistence of granzyme B+ effector memory 19BB zeta CAR T cells and enhanced sustainably their antitumor activity both in vitro and in vivo. Consistent with their long-lasting antitumor activity, PRC2-inhibited 19BB zeta CAR T cells did not exhibit signs of exhaustion over time. Furthermore, TCR restimulation along with PRC2 inhibition promoted the differentiation of patient-derived anti-CD19 effector memory CAR T cells with enhanced cytotoxic features and elicited potent antitumor responses. In line with this, the gene signature derived from in-house PRC2-inhibited 19BB zeta CAR T cells was enriched in tisagenlecleucel BB zeta CAR T-cell therapy responders with large B-cell lymphoma. Collectively, our results demonstrated that targeting PRC2 may be a promising approach to enhance a functional effector program in CAR T cells against hematologic malignancies.Significance: Selective inhibition of PRC2 endows 19BB zeta CAR T cells with cytotoxic and effector memory features that are associated with improved antitumor activity and better response to CAR T-cell therapy. (AU)

• Processo FAPESP: 22/00747-8 - Avaliação do potencial antitumoral de células T CD39+ em pacientes com carcinoma renal de células claras
• Beneficiário: Emmanuel Vinicius Oliveira Araujo
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 20/10299-7 - PIWIL4 como regulador epigenético central de elementos retrovirais endógenos no Câncer Gástrico: implicações na imunopatogênese e imunoterapia da doença?
• Beneficiário: Glauco Akelinghton Freire Vitiello
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 19/25129-2 - Caracterização detalhada das células T em Adenocarcinomas Ductais Pancreáticos
• Beneficiário: Gabriela Sarti Kinker
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 14/50943-1 - INCT 2014: de Oncogenômica e Inovação Terapêutica
• Beneficiário: Dirce Maria Carraro
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 18/14034-8 - Caracterização dos perfis da cromatina e transcricional de células T de pacientes com adenocarcinoma gástrico como estratégia para o descobrimento de alvos imunoterapêuticos
• Beneficiário: Tiago da Silva Medina
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores
• Processo FAPESP: 21/00643-5 - Caracterização dos perfis da cromatina e transcricional de células T de pacientes com adenocarcinoma gástrico como estratégia para o descobrimento de alvos imunoterapêuticos
• Beneficiário: Maria Letícia Rodrigues Carvalho
• Modalidade de apoio: Bolsas no Brasil - Mestrado